Bioprocessing White Papers

  1. An Overview Of 2026 Life Sciences Industry Trends 6/3/2026

    Explore the paradigm shift reshaping life sciences. Learn how connecting data streams across the product lifecycle drives predictive compliance and operational excellence.

  2. Smarter By The Second Redefining Pharma Biopharma Manufacturing 6/2/2026

    Continuous monitoring is transforming manufacturing. With advanced analytics and sensor technologies, teams can detect issues early and optimize processes in real time for greater efficiency.

  3. Unlocking Operational Capacity With Digitalized Cleaning Validation 6/2/2026

    Digitalizing cleaning validation reduces inefficiencies, strengthens data integrity, and improves audit readiness. See how integrated systems can continuously optimize manufacturing performance.

  4. End-To-End Process Scalability Of HEK 293 Media For High Titer AAV Production 6/2/2026

    Explore how controlled bioreactor environments enable optimization of critical process parameters and support robust, scalable AAV production from development through manufacturing.

  5. T Cells In Immunotherapies: The Key Progress Underway 6/1/2026

    CAR-T therapies now make up 73% of active pipeline programs, yet solid tumors remain largely out of reach. Where is T cell immunotherapy headed next, and what does it mean for your pipeline strategy?

  6. Speeding Up Safety: An Evaluation Of Mycoplasma Technology 5/27/2026

    Rapid mycoplasma testing enhances cell and gene therapy safety by reducing turnaround time, minimizing sample needs, and delivering sensitive, reliable contamination detection across diverse matrices.

  7. Untapped Potential In Animal Health Innovation 5/26/2026

    Animal health innovation is driving rapid market growth, fueled by rising demand and complexity, creating opportunities for advanced therapies, sustainability, and better disease management.

  8. A Platform That's Revolutionizing Biopharma Manufacturing 5/26/2026

    Integrated platform boosts biologics manufacturing by raising protein yield, speeding timelines, and improving scalability via cell line development, process optimization, and data-driven design.

  9. Why Strategic Outsourcing In Biologics Is No Longer Optional 5/26/2026
  10. Antibody Drug Conjugates Re-Emergence Of An Old Modality 5/26/2026

    Antibody-drug conjugates link targeted antibodies with potent drugs to treat cancer more precisely, though challenges remain in stability, conjugation, and scalable production.